Newleos Therapeutics

Engrail Therapeutics

This company develops small-molecule therapies for patients with neurologic, neuropsychiatric and neurodevelopmental disorders such as anxiety, depression and rare diseases.

Synendos Therapeutics

This company develops small molecule inhibitors to treat patients with central nervous system disorders, such as anxiety and post-traumatic stress disorder.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Draig Therapeutics

The company develops neuromodulators and receptor potentiators for patients with major depressive disorder and other neuropsychiatric conditions.

Amygdala Neurosciences

This biopharmaceutical company develops oral enzyme inhibitors to treat substance use disorders by reducing cravings and preventing relapse in patients.

Neurosterix

This biopharmaceutical company develops allosteric modulator therapeutics to treat patients suffering from neurological and neuropsychiatric disorders, including schizophrenia and mood disorders.

Syremis Therapeutics

This biopharmaceutical company develops small-molecule oral medicines for patients with neuropsychiatric conditions, including schizophrenia, major depressive disorder and bipolar depression.